These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 39101180

  • 1. Immune checkpoint inhibitor-related type 1 diabetes mellitus which develops long after treatment discontinuation: a case report and review of literature.
    Obata Y, Takemoto M, Sakaue TA, Kawata S, Mukai K, Miyashita K, Kozawa J, Nishizawa H, Shimomura I.
    Diabetol Int; 2024 Jul; 15(3):605-610. PubMed ID: 39101180
    [Abstract] [Full Text] [Related]

  • 2. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
    Yaura K, Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z.
    Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
    [Abstract] [Full Text] [Related]

  • 3. Case report: Strong GAD antibody positivity and type 1 diabetes-HLA-susceptible haplotype-DRB1*04:05-DQB1*04:01 in a Japanese patient with immune checkpoint inhibitor-induced type 1 diabetes.
    Yabuki S, Hirai H, Moriya C, Kusano Y, Hasegawa T.
    Front Endocrinol (Lausanne); 2024 Aug; 15():1407192. PubMed ID: 38841300
    [Abstract] [Full Text] [Related]

  • 4. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C.
    J Immunother Cancer; 2017 Aug; 5():40. PubMed ID: 28515940
    [Abstract] [Full Text] [Related]

  • 5. Two cases with fulminant type 1 diabetes that developed long after cessation of immune checkpoint inhibitor treatment.
    Hatayama S, Kodama S, Kawana Y, Otake S, Sato D, Horiuchi T, Takahashi K, Kaneko K, Imai J, Katagiri H.
    J Diabetes Investig; 2022 Aug; 13(8):1458-1460. PubMed ID: 35396830
    [Abstract] [Full Text] [Related]

  • 6. Atezolizumab-induced fulminant type 1 diabetes mellitus occurring four months after treatment cessation.
    Nishioki T, Kato M, Kataoka S, Miura K, Nagaoka T, Takahashi K.
    Respirol Case Rep; 2020 Dec; 8(9):e00685. PubMed ID: 33224504
    [Abstract] [Full Text] [Related]

  • 7. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
    Kedzior SK, Jacknin G, Hudler A, Mueller SW, Kiser TH.
    Am J Case Rep; 2021 Jun 29; 22():e931702. PubMed ID: 34185763
    [Abstract] [Full Text] [Related]

  • 8. Clinical and HLA genotype analysis of immune checkpoint inhibitor-associated diabetes mellitus: a single-center case series from China.
    Liu YC, Liu H, Zhao SL, Chen K, Jin P.
    Front Immunol; 2023 Jun 29; 14():1164120. PubMed ID: 37359544
    [Abstract] [Full Text] [Related]

  • 9. Atezolizumab-Induced Type 1 Diabetic Ketoacidosis in a Patient With Small Cell Lung Cancer and Pre-existing Type 2 Diabetes Mellitus.
    Narumoto K, Oda N, Mitani R, Takata I.
    Cureus; 2024 Mar 29; 16(3):e57024. PubMed ID: 38681275
    [Abstract] [Full Text] [Related]

  • 10. Late-onset acute type 1 diabetes mellitus 7 months after discontinuation of pembrolizumab against lung cancer.
    Ichihara S, Kunishige M, Kadota N, Okano Y, Machida H, Hatakeyama N, Naruse K, Shinohara T, Takeuchi E.
    Thorac Cancer; 2023 Jan 29; 14(1):81-84. PubMed ID: 36411591
    [Abstract] [Full Text] [Related]

  • 11. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S, Hakozaki T, Kitadai R, Hosomi Y.
    Thorac Cancer; 2020 Jul 29; 11(7):1927-1933. PubMed ID: 32421224
    [Abstract] [Full Text] [Related]

  • 12. Type 1 diabetes associated with immune checkpoint inhibitors for malignant melanoma: A case report and review of 8 cases.
    Ishiguro A, Ogata D, Ohashi K, Hiki K, Yamakawa K, Jinnai S, Tsutsui K, Takahashi A, Namikawa K, Yamazaki N.
    Medicine (Baltimore); 2022 Sep 02; 101(35):e30398. PubMed ID: 36107581
    [Abstract] [Full Text] [Related]

  • 13. Case of slowly progressive type 1 diabetes mellitus with drastically reduced insulin secretory capacity after immune checkpoint inhibitor treatment for advanced renal cell carcinoma.
    Yamaguchi H, Miyoshi Y, Uehara Y, Fujii K, Nagata S, Obata Y, Kosugi M, Hazama Y, Yasuda T.
    Diabetol Int; 2021 Apr 02; 12(2):234-240. PubMed ID: 33786278
    [Abstract] [Full Text] [Related]

  • 14. Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy - A comprehensive cancer center experience.
    Zhang Z, Sharma R, Hamad L, Riebandt G, Attwood K.
    Diabetes Res Clin Pract; 2023 Aug 02; 202():110776. PubMed ID: 37311494
    [Abstract] [Full Text] [Related]

  • 15. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
    Hong AR, Yoon JH, Kim HK, Kang HC.
    Front Endocrinol (Lausanne); 2020 Aug 02; 11():14. PubMed ID: 32047478
    [Abstract] [Full Text] [Related]

  • 16. Characterization of immune checkpoint inhibitor-associated fulminant type 1 diabetes associated with autoantibody status and ethnic origin.
    Qiu J, Luo S, Yin W, Guo K, Xiang Y, Li X, Liu Z, Zhou Z.
    Front Immunol; 2022 Aug 02; 13():968798. PubMed ID: 36451831
    [Abstract] [Full Text] [Related]

  • 17. Type 1 diabetes mellitus affected by potential toxicity from long-term use of nivolumab.
    Motomura Y, Urai S, Hirota Y, Takegawa N, Bando H, Yamamoto M, Fukuoka H, Tsuda M, Ogawa W.
    Diabetol Int; 2024 Jan 02; 15(1):130-134. PubMed ID: 38264226
    [Abstract] [Full Text] [Related]

  • 18. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.
    de Filette JMK, Pen JJ, Decoster L, Vissers T, Bravenboer B, Van der Auwera BJ, Gorus FK, Roep BO, Aspeslagh S, Neyns B, Velkeniers B, Kharagjitsingh AV.
    Eur J Endocrinol; 2019 Sep 02; 181(3):363-374. PubMed ID: 31330498
    [Abstract] [Full Text] [Related]

  • 19. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
    Grimmelmann I, Momma M, Zimmer L, Hassel JC, Heinzerling L, Pföhler C, Loquai C, Ruini C, Utikal J, Thoms KM, Kähler KC, Eigentler T, Herbst RA, Meier F, Debus D, Berking C, Kochanek C, Ugurel S, Gutzmer R, German Dermatooncology Group (DeCOG).
    Eur J Cancer; 2021 May 02; 149():1-10. PubMed ID: 33812141
    [Abstract] [Full Text] [Related]

  • 20. A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.
    Marsiglio J, McPherson JP, Kovacsovics-Bankowski M, Jeter J, Vaklavas C, Swami U, Grossmann D, Erickson-Wayman A, Soares HP, Kerrigan K, Gibson B, Doherty JA, Hyngstrom J, Hardikar S, Hu-Lieskovan S.
    Front Immunol; 2023 May 02; 14():1229823. PubMed ID: 37671166
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.